- Tea and Coffee May Help Protect You From Some Cancers
- Too Much Acetaminophen Could Harm Seniors’ Health
- Last Year’s Platinum-Based Drugs Shortage Didn’t Raise Cancer Deaths, Study Found
- Autism Tops List of Worldwide Youth Health Issues
- Dancing Helps People With Parkinson’s In More Ways Than One
- Flu Cases Start to Surge as Americans Prepare for Holiday Gatherings
- GLP-1 Zepbound Is Approved As First Drug For Sleep Apnea
- Feeling Appreciated by Partner is Critical for Caregiver’s Mental Health
- Chatbot “Brains” May Slow with Age
- More of America’s Pets Are Overdosing on Stray Coke, Meth
Health Highlights: Aug. 1, 2014
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:
FDA to Regulate Medical Lab Testing
Tests developed and performed by medical labs will now be regulated by the U.S. Food and Drug Administration, the agency said Thursday.
In announcing the change, the FDA said these tests often determine critical treatment decisions, so more oversight is needed.
Tests that are sold to hospitals, laboratories, doctors’ offices and the public have been regulated as medical devices for years, according to the New York Times. However, tests developed and performed by a single laboratory have not been regulated. Until now, the agency has claimed it had the authority to do so, but had chosen not to, the newspaper reported.
There are an estimated 11,000 lab-developed tests offered by 2,000 laboratories, according to the Times. Advances in DNA sequencing have spurred the growth of personalized medicine, in which genetic lab tests are used to tailor treatments for individuals with diseases such as cancer, the agency said.
“Inaccurate test results could cause patients to seek unnecessary treatment, or delay and sometimes forgo treatment altogether,” FDA Commissioner Dr. Margaret Hamburg said in an FDA news release. The policy change “demonstrates the agency’s commitment to personalized medicine, which depends on accurate and reliable tests to get the right treatment to the right patient.”
The change has been opposed by some in the industry, who have claimed it would increase the cost of developing such tests and curb innovation, the Times reported.
But the FDA noted it would slowly implement the regulations over a nine-year period and would focus on tests where a wrong result would pose the highest risk for patients. It also said it would exempt tests for which there is no approved alternative and tests for rare diseases, the Times reported.
Copyright © 2024 HealthDay. All rights reserved.